Achieve Life Sciences (ACHV) Share-based Compensation (2010 - 2026)
Achieve Life Sciences' (ACHV) quarterly Share-based Compensation came in at $9.1 million in Q1 2026, up 307.71% YoY from $2.2 million in Q1 2025, and up 221.98% on a QoQ basis from -$7.5 million in Q4 2025.
Achieve Life Sciences (ACHV) Share-based Compensation (2010 - 2026) Analysis & Trends
Achieve Life Sciences (ACHV) has 17 years of Share-based Compensation data on file, last reported at $9.1 million in Q1 2026.
- Quarterly Share-based Compensation rose 307.71% year-over-year to $9.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.1 million (up 760.11% YoY) and the FY2025 annual result came in at $2.9 million, up 20.83% from the prior year.
- Share-based Compensation improved to $9.1 million in Q1 2026, from -$7.5 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $9.1 million in Q1 2026 to a low of -$7.5 million in Q4 2025.
- A 5-year average of $1.2 million and a median of $1.3 million in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation soared 547.77% — and 2024, when it slumped 216.71%.
- Tracing ACHV's Share-based Compensation over 5 years: stood at $3.2 million in 2022, then advanced by 6.25% to $3.4 million in 2023, then tumbled by 216.71% to -$4.0 million in 2024, then sank by 88.0% to -$7.5 million in 2025, then jumped by 221.98% to $9.1 million in 2026.
- The last three Share-based Compensation figures came in at $9.1 million (Q1 2026), -$7.5 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Achieve Life Sciences | 330.88 Mn | 330.88 Mn | - | 16.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.80 Mn |
| Jun 30, 2026 | 16.80 Mn |
| Mar 31, 2026 | 9.10 Mn |
| Mar 31, 2026 | 9.10 Mn |
| Dec 31, 2025 | -7.46 Mn |
| Dec 31, 2025 | -7.46 Mn |
| Sep 30, 2025 | 1.70 Mn |
| Sep 30, 2025 | 1.70 Mn |
| Jun 30, 2025 | 2.89 Mn |
| Jun 30, 2025 | 2.89 Mn |
| Mar 31, 2025 | 2.23 Mn |
| Mar 31, 2025 | 2.23 Mn |
| Dec 31, 2024 | -3.97 Mn |
| Dec 31, 2024 | -3.97 Mn |
| Sep 30, 2024 | 1.34 Mn |
| Sep 30, 2024 | 1.34 Mn |
| Jun 30, 2024 | 1.45 Mn |
| Jun 30, 2024 | 1.45 Mn |
| Mar 31, 2024 | 1.29 Mn |
| Mar 31, 2024 | 1.29 Mn |